FIG 8.

Effects of combining polycations with ruxolitinib on VSV infection and oncolysis in other PDAC cell lines. Cells were pretreated with 10 μg/ml Polybrene or DEAE-dextran or mock treated for 30 min, and VSV-ΔM51-GFP at an MOI of 0.001 (cell line specific) was then added in the presence of polycations (or mock treated) for 1 h at 37°C, followed by medium removal, washes with PBS, and then incubation in the presence of 2.5 μM ruxolitinib or mock treatment. VSV infection-associated GFP fluorescence was monitored for 68 h, and an MTT assay was then performed to determine cell viability. The assay was done in triplicate, and data represent the means ± standard errors of the means. For GFP fluorescence, conditions were compared by using 2-way analysis of variance followed by the Dunnett posttest for comparison to mock treatment. ****, P < 0.0001. The MTT conditions were compared by using 1-way analysis of variance followed by the Dunnett posttest for comparison to mock treatment (or also to VSV plus ruxolitinib for the last three conditions). *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.